Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04483817
Other study ID # EC 06/2019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 17, 2019
Est. completion date September 1, 2023

Study information

Verified date August 2022
Source Fisiocore LC,SL
Contact Laura Calzado Sanz, Physiotherap
Phone +34 626495479
Email lauracalzado@lcfisioterapia.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of this study, is compare the effectiveness of transcutaneous posterior tibial nerve stimulation versus percutaneous posterior nerve stimulation in patients with overactive bladder.


Description:

Overactive bladder syndrome (OAB) is a set of symptoms characterized by urge, with or without urge incontinence, usually with frequency and nocturia in the absence of urinary infection or other pathologies. OAB affect considerably the quality of life of the subject who suffer. The first line of treatment is a conservative management as behavioral interventions, followed by pharmacological management as antimuscarinic or antimuscarinic drugs. Percutaneous tibial nerve stimulation (PTNS) is present as another alternative of treatment. Previous studies have shown the positive effects of PTNS in a reduction on OAB symptoms. The PTNS was described by Stoller in 1999. It's a electrical stimulation of the tibial nerve, inserting a 34 gauge needle at a 60º angle, 5 cm cephalad to the malleolus and 1 cm posterior of the tibia, to stimulation of the sacral segments S2 and S3, where the spinal centre of bladder is located. The parameters used are 20Hz and 200 µs, 12 sessions, two weekly, 30 min treatment. The PTNS is a minimal invasive technique, but can be utilized surface electrodes instead of needle to minimize the discomfort of prick. The main aim of this study, is compare the effectiveness of transcutaneous posterior tibial nerve stimulation versus percutaneous posterior nerve stimulation in patients with overactive bladder.


Recruitment information / eligibility

Status Recruiting
Enrollment 104
Est. completion date September 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects diagnosis of overactive bladder - Subjects refractory to treatments antimuscarinic or beta 3-agonist - Subjects who do not take restricted medication - Subjects who can cognitively complete the voiding diary and questionnaires - Subject with symptoms 3 months ago - Men must be discarded obstruction by benign prostatic hyperplasia Exclusion Criteria: - Subjects with stress incontinence - Subjects with urinary tract infection - Subjects with neurological disease - Subjects with pacemakers fitted - Pregnancy - Subjects who have disorder sensitive - A history of pelvic tumors - Subject who is not able to understand the physiotherapist

Study Design


Intervention

Device:
Transcutaneous tibial nerve stimulation
Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
Percutaneous tibial nerve stimulation
Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.

Locations

Country Name City State
Spain Laura Calzado Sanz Alcalá de Henares Madrid

Sponsors (1)

Lead Sponsor Collaborator
Fisiocore LC,SL

Country where clinical trial is conducted

Spain, 

References & Publications (6)

Booth J, Connelly L, Dickson S, Duncan F, Lawrence M. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review. Neurourol Urodyn. 2018 Feb;37(2):528-541. doi: 10.1002/nau.23351. E — View Citation

Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012 Nov;31(8):1206-16. doi: 10.1002/nau.22251. Epub 2012 May 11. Review. — View Citation

Civic D, Black E. Re: Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial: K. M. Peters, D. J. Carrico, R. A. Perez-Marrero, A. U. Khan, L. S. Wooldri — View Citation

Sajadi KP, Goldman HB. Percutaneous tibial nerve stimulation and overactive bladder. Curr Urol Rep. 2010 Sep;11(5):293-5. doi: 10.1007/s11934-010-0126-4. — View Citation

Wibisono E, Rahardjo HE. Effectiveness of Short Term Percutaneous Tibial Nerve Stimulation for Non-neurogenic Overactive Bladder Syndrome in Adults: A Meta-analysis. Acta Med Indones. 2015 Jul;47(3):188-200. Review. — View Citation

Yoong W, Ridout AE, Damodaram M, Dadswell R. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int. 2010 Dec;106(11):1673-6. doi: 10.1111/j.1464-4 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary frequency Urinary episodes per day.
According to international consensus, it is considered pathological when:
There are more than 8 episodes of urination per day
two years
Primary Nightime voids Urinary episodes per night.
According to international consensus, it is considered pathological when:
There is more than 1 episode per night.
two years
Primary Urge episodes Urinary urge episodes per day. The degree of urgency is measured through the PPIUS scale (outcome no. 4). A grade 3-4 on the PPIUS scale is considered pathological. two years
Primary Degree of urge to void Measured through the PPIUS (Patient Perception of Intensity of Urgency Scale).
Scale from 0 to 4, where:
0 = No urgency;
= Slight urgency;
= Moderate urgency;
= severe urgency;
= urge incontinence.
two years
Primary Voided volume Urine 24 hours volume. Voiding volume over 3000cc in 24 hours, is considered pathological. two years
Secondary Overactive Bladder questionnaire Short- Form (OABq-SF) This is a questionnaire that evaluates both the symptoms and the quality of life of the patient:
Symptom involvement (6 questions): Score of 6-36
Quality of life (13 questions): Score of 13-78
0-100 metric scale. The higher the score, the more severity.
Two years
Secondary International Consultation on Incontinence Questionnaire (ICIQ-SF) This is a self-administered questionnaire that identifies people with urine incontinence (UI) and also assess the impact on quality of life. ICIQ-SF Score: Adding the scores to questions 1+2+3, a score above zero is considered a diagnosis of UI. Two years
Secondary Benefits, satisfaction and willingness to continue to treatment (BSW) The BSD12 questionnaire is a 3 item likert-type questionnaire (benefit, satisfaction and willingness) with an overall score of 0 to 10. Higher scores indicates a better perception of benefit and satisfaction with the treatment, and a greater willingness to continue with it. Two years
See also
  Status Clinical Trial Phase
Completed NCT02540707 - Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Phase 4
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Not yet recruiting NCT06438861 - Role of Combination Therapy in Women With Refractory Overactive Bladder N/A
Completed NCT01114412 - Basic Sensations Coming From the Bladder
Recruiting NCT06045728 - Telerehabilitation for Overactive Bladder Syndrome in Obese Women N/A
Recruiting NCT03952299 - Oxybutynin for Post-surgical Bladder Pain and Urgency Phase 3
Active, not recruiting NCT03758235 - Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin Phase 3
Completed NCT01912885 - Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome N/A
Completed NCT04300400 - Treatment of the Overactive Bladder Syndrome: A Delphi Study
Recruiting NCT04982120 - Use of Repris Needle in Bladder Injection N/A
Completed NCT06123364 - Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder N/A
Recruiting NCT06088394 - Effect of Acupuncture Augmented With Pelvic Floor Exercises on Overactive Bladder N/A
Recruiting NCT05221021 - Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome Phase 4
Terminated NCT04256876 - TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) N/A
Not yet recruiting NCT03331081 - Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome N/A
Recruiting NCT04873037 - BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder N/A
Completed NCT02024945 - Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome Phase 4
Completed NCT00546637 - Fesoterodine "add-on" Male Overactive Bladder Study Phase 3
Not yet recruiting NCT06143397 - Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis. N/A
Recruiting NCT03044912 - Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan Phase 3